Pfizer strengthens board of directors

Pfizer has bolstered its board of directors with the appointment of Ronald Blaylock, who joins with immediate effect.

Blaylock currently serves as managing partner of private equity firm GenNx360 Capital Partners, which he founded in 2006.

Prior to this, he founded investment banking firm Blaylock & Company in 1993, subsequently serving as chairman and chief executive officer.

He brings further senior management experience from Paine Webber and CitiGroup, and currently serves on the boards of CarMax, Radio One, WR Berkley and Syncreon.

Ian Read, Pfizer's chairman and chief executive officer, said: “We are pleased to welcome Ron Blaylock to Pfizer's board of directors.

“He brings business, financial and leadership expertise, which will be an asset to Pfizer's diverse board and to our company. The addition of Ron to our board helps to ensure that Pfizer continues to benefit from a breadth and variety of experience.”